Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

NCT00210379 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, B Cell

Interventions

DRUG: rituximab
DRUG: CHOP
DRUG: intrathecal methotrexate
PROCEDURE: radiotherapy

Sponsor

International Extranodal Lymphoma Study Group (IELSG)